The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 315.00
Bid: 315.00
Ask: 317.50
Change: -12.00 (-3.67%)
Spread: 2.50 (0.794%)
Open: 325.50
High: 329.50
Low: 315.00
Prev. Close: 327.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SMALL-CAP WINNERS & LOSERS: ME Group upgrades outlook on robust demand

Mon, 14th Nov 2022 11:22

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Monday.

----------

SMALL-CAP - WINNERS

----------

ME Group International PLC, up 8.8% at 103.18 pence, 12-month range 55.70p - 119.50p. Upgrades its full-year outlook thanks to a first-half performance which came in ahead of expectations. The instant-service equipment firm notes a strong recovery across continental Europe and robust consumer demand for all its services. Revenue is now expected to be between GBP256 million and GBP262 million for the full-year year ended October 31, up from GBP257 million previously. Earnings before interest, taxation, depreciation, and amortisation is now expected between GBP82 million and GBP85 million, up from between GBP79 million and GBP84 million previously.

----------

Oxford BioMedica PLC, up 3.0% at 336.74 pence, 12-month range 276.62p - 1,526.00p. Completes the sale of its Windrush Court laboratory facility for GBP60 million, exceeding its target offer figure of GBP55 million. This, the biotechnology firm explains, strengthens its cash position to more than GBP150 million. In addition, the firm is granted an occupational leaseback of Windrush for 15 years at a rent of GBP3.5 million per year, rising to GBP4.7 million per year after five years.

----------

CT Private Equity Trust PLC, up 2.7% at 429.90 pence, 12-month range 375.51p - 520.00p. Sells a portion of its investment in the Italian funeral services of business of San Siro, part of funeral services firm HOFI Spa, and its related entities. At June 30, the firm's investment in San Siro was valued at EUR13.2 million. Firm sells its investment for GBP11.4 million, representing an uplift of GBP23.1 million, or 4.8% of the company June 30 net asset value. 25% of the total proceeds from the sale will be re-invested into a new investment in HOFI Spa, it adds.

----------

SMALL-CAP - LOSERS

----------

Ondo InsurTech PLC, down 3.3% at 7.25 pence, 12-month range 5.00p - 13.40p. In the six months ended August 31, widens its pretax loss to GBP2.1 million from GBP1.6 million the previous year. This comes as the firm books a GBP706,000 reverse acquisition expense in the period, and costs of sales rise to GBP511,000 from GBP475,000. Revenue, meanwhile, jumps to GBP1.0 million from GBP646,000 the year prior. Ondo says this revenue growth was driven by a growth in registered devices, which were up 43% against the prior year. "While today's economic situation is challenging, we are well placed to weather the storm... We are managing upward cost pressures on our hardware costs successfully, and although we have seen some cost increases, we have managed to pass these on to our customers," the firm adds.

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
28 Jan 2022 16:19

CORRECT: Oxford BioMedica to acquire 80% ownership of new US business

CORRECT: Oxford BioMedica to acquire 80% ownership of new US business

Read more
28 Jan 2022 12:13

LONDON MARKET MIDDAY: Stocks sink on Ukraine tensions and hawkish Fed

LONDON MARKET MIDDAY: Stocks sink on Ukraine tensions and hawkish Fed

Read more
28 Jan 2022 10:27

Oxford BioMedica to acquire 80% ownership of new US virus business

Oxford BioMedica to acquire 80% ownership of new US virus business

Read more
28 Jan 2022 09:56

Oxford Biomedica creates venture with Homology, launches £80m fundraise

(Sharecast News) - Cell and gene therapy specialist Oxford Biomedica announced an agreement with Homology Medicines on Friday, as well as a placing to raise £80m from new and existing shareholders, including a retail offer through the PrimaryBid platform.

Read more
17 Jan 2022 09:32

Oxford Biomedica starts search for new CEO as Dawson steps down

Oxford Biomedica starts search for new CEO as Dawson steps down

Read more
17 Jan 2022 07:10

Oxford Biomedica CEO John Dawson to step down

(Sharecast News) - Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm which helped develop a Covid-19 vaccine with AstraZeneca.

Read more
5 Jan 2022 08:54

Oxford Biomedica wins new agreement for LentiVector platform

Oxford Biomedica wins new agreement for LentiVector platform

Read more
5 Jan 2022 07:29

Oxford Biomedica signs licence, supply deal with Cabaletta Bio

(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.

Read more
15 Dec 2021 09:33

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

LONDON BROKER RATINGS: BofA starts Pod Point at Buy; Barclays cuts DCC

Read more
13 Dec 2021 10:03

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Oxford Biomedica in license and supply deals with Novartis and Arcellx

Read more
13 Dec 2021 07:31

Oxford Biomedica strikes new license and supply agreements

(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck new license and supply agreements for its lentiviral vectors.

Read more
19 Oct 2021 10:50

Oxford BioMedica licences technology for cystic fibrosis treatment

Oxford BioMedica licences technology for cystic fibrosis treatment

Read more
19 Oct 2021 09:18

Boehringer Ingelheim licenses Oxford Biomedica's lentiviral vector technology

(Sharecast News) - Gene and cell therapy firm Oxford Biomedica said on Tuesday that pharmaceutical giant Boehringer Ingelheim had exercised its option to license its lentiviral vector technology to manufacture, register and commercialise a treatment for cystic fibrosis.

Read more
30 Sep 2021 09:35

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

LONDON BROKER RATINGS: Keppler Cheuvreux raises Pearson to Hold

Read more
28 Sep 2021 09:40

LONDON BROKER RATINGS: Investec prefers 888 over Entain

LONDON BROKER RATINGS: Investec prefers 888 over Entain

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.